(Total Views: 222)
Posted On: 07/24/2018 3:58:06 PM
Post# of 102731
$STLT news
https://ir.spotlightinnovation.com/press-releases/detail/91
That grant is worth 50% of the market cap at the bid, wake up peeps!!! OS is 30 mil shares, >70% + owned by the 2 founders/CEO/Directors
First product Biotech pain killer using cobra venom now at sale on line at Walmart and at stores "Venodol" I use it, it works!!!
No side effects.
Spotlight Innovation Spinal Muscular Atrophy Research Collaborator Professor Kevin Hodgetts Receives $300,000 Grant from Cure SMA
Download as PDF
July 24, 2018
URBANDALE, IA, July 24, 2018 (GLOBE NEWSWIRE) -- Spotlight Innovation Inc. (OTCQB: STLT), a pharmaceutical company targeting rare, emerging and neglected diseases, today announced that Company research collaborator Professor Kevin Hodgetts has been awarded a grant of $300,000 by the nonprofit organization Cure SMA for the project Pre-Clinical Development of LDN-5178 for the Treatment of SMA.
“Cure SMA's support of Professor Hodgetts to work with Dr. Elliot Androphy and other collaborators on SMA drug candidate LDN-5178 represents an important validation of Spotlight Innovation's preclinical SMA pipeline,” said Geoffrey Laff, Ph.D., Spotlight Innovation's Senior Vice President of Business Development.
Spotlight Innovation holds an exclusive, worldwide development and commercialization license from Indiana University Innovation and Commercialization Office for LDN-5178 and a group of related compounds including STL-182.
Professor Hodgetts, director of the Laboratory for Drug Discovery in Neurodegeneration at Brigham and Women's Hospital, and Dr. Androphy of Indiana University School of Medicine, are members of Spotlight Innovation's Scientific Advisory Board.
For more information about Cure SMA and this grant award, visit www.curesma.org/news/hodgetts-grant-2018.html.
About Spotlight Innovation Inc.
Spotlight Innovation Inc. (OTCQB: STLT) acquires and develops proprietary therapies to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. The Company identifies in-licensing opportunities and manages product development through partnerships with universities, medical schools, contract research organizations (CROs), and contract manufacturing organizations (CMOs). Spotlight Innovation’s development pipeline includes product candidates for cancer, chronic pain, spinal muscular atrophy (SMA) and Zika virus infection. At the appropriate stage of research and development the Company will endeavor to pursue product commercialization opportunities including, but not limited to, out-licensing and strategic partnerships with industry leaders. For more information, visit www.spotlightinnovation.com or www.twitter.com/spotlightinno.
https://ir.spotlightinnovation.com/press-releases/detail/91
That grant is worth 50% of the market cap at the bid, wake up peeps!!! OS is 30 mil shares, >70% + owned by the 2 founders/CEO/Directors
First product Biotech pain killer using cobra venom now at sale on line at Walmart and at stores "Venodol" I use it, it works!!!
No side effects.
Spotlight Innovation Spinal Muscular Atrophy Research Collaborator Professor Kevin Hodgetts Receives $300,000 Grant from Cure SMA
Download as PDF
July 24, 2018
URBANDALE, IA, July 24, 2018 (GLOBE NEWSWIRE) -- Spotlight Innovation Inc. (OTCQB: STLT), a pharmaceutical company targeting rare, emerging and neglected diseases, today announced that Company research collaborator Professor Kevin Hodgetts has been awarded a grant of $300,000 by the nonprofit organization Cure SMA for the project Pre-Clinical Development of LDN-5178 for the Treatment of SMA.
“Cure SMA's support of Professor Hodgetts to work with Dr. Elliot Androphy and other collaborators on SMA drug candidate LDN-5178 represents an important validation of Spotlight Innovation's preclinical SMA pipeline,” said Geoffrey Laff, Ph.D., Spotlight Innovation's Senior Vice President of Business Development.
Spotlight Innovation holds an exclusive, worldwide development and commercialization license from Indiana University Innovation and Commercialization Office for LDN-5178 and a group of related compounds including STL-182.
Professor Hodgetts, director of the Laboratory for Drug Discovery in Neurodegeneration at Brigham and Women's Hospital, and Dr. Androphy of Indiana University School of Medicine, are members of Spotlight Innovation's Scientific Advisory Board.
For more information about Cure SMA and this grant award, visit www.curesma.org/news/hodgetts-grant-2018.html.
About Spotlight Innovation Inc.
Spotlight Innovation Inc. (OTCQB: STLT) acquires and develops proprietary therapies to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. The Company identifies in-licensing opportunities and manages product development through partnerships with universities, medical schools, contract research organizations (CROs), and contract manufacturing organizations (CMOs). Spotlight Innovation’s development pipeline includes product candidates for cancer, chronic pain, spinal muscular atrophy (SMA) and Zika virus infection. At the appropriate stage of research and development the Company will endeavor to pursue product commercialization opportunities including, but not limited to, out-licensing and strategic partnerships with industry leaders. For more information, visit www.spotlightinnovation.com or www.twitter.com/spotlightinno.
(0)
(0)
